Close

Form SC 13D/A VERMILLION, INC. Filed by: FEINBERG LARRY N

December 24, 2014 4:26 PM EST
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.� 20549


SCHEDULE 13D
(Amendment No. 3)
Under the Securities Exchange Act of 1934*



Vermillion, Inc.

(Name of Issuer)
Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)
92407M206
(CUSIP Number)
Larry N. Feinberg
c/o Oracle Investment Management, Inc.
200 Greenwich Avenue
Greenwich, CT 06830
(203) 862-7900

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

With a copy to:

Rita Molesworth, Esq.
Jeffrey Hochman, Esq.
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
(212) 728-8000

December 23, 2014

(Date of Event which Requires
Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of �� 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: 
NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.� See Rule 240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
1

SCHEDULE 13D
CUSIP No. 92407M206
Page 2 of 12 pages
1
NAMES OF REPORTING PERSONS
Larry N. Feinberg
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)� 
(b)� 
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
N/A
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
�
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
8,112,182
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
8,112,182
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,112,182
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
�
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.82%*
14
TYPE OF REPORTING PERSON (See Instructions)
IN
*� Calculated based on a total of 43,110,014 shares of common stock outstanding as of December 18, 2014, according to information furnished by Vermillion, Inc. on December 23, 2014.
2


SCHEDULE 13D
CUSIP No.� 92407M206
Page 3 of 12 pages
1
NAMES OF REPORTING PERSONS
Oracle Associates, LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)� 
(b)� 
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
N/A
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
� 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
8,112,182
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
8,112,182
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,112,182
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
�
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.82%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
*� Calculated based on a total of 43,110,014 shares of common stock outstanding as of December 18, 2014, according to information furnished by Vermillion, Inc. on December 23, 2014.
3

SCHEDULE 13D
CUSIP No.� 92407M206
Page 4 of 12 pages
1
NAMES OF REPORTING PERSONS
Oracle Partners, L.P.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)� 
(b)� 
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
OO
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
� 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
4,543,980
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
4,543,980
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,543,980
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
� 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.54%*
14
TYPE OF REPORTING PERSON (See Instructions)
PN
*� Calculated based on a total of 43,110,014 shares of common stock outstanding as of December 18, 2014, according to information furnished by Vermillion, Inc. on December 23, 2014.
4

SCHEDULE 13D
CUSIP No.� 92407M206
Page 5 of 12 pages
1
NAMES OF REPORTING PERSONS
Oracle Investment Management, Inc.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)� 
(b)� 
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
N/A
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
� 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
2,595,980
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
2,595,980
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,595,980
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
� 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.02%*
14
TYPE OF REPORTING PERSON (See Instructions)
CO
*� Calculated based on a total of 43,110,014 shares of common stock outstanding as of December 18, 2014, according to information furnished by Vermillion, Inc. on December 23, 2014.
5

SCHEDULE 13D
CUSIP No.� 92407M206
Page 6 of 12 pages
1
NAMES OF REPORTING PERSONS
Oracle Ten Fund Master, LP
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)� 
(b)� 
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
OO
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
� 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
2,595,980
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
2,595,980
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,595,980
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
� 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.02%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
*� Calculated based on a total of 43,110,014 shares of common stock outstanding as of December 18, 2014, according to information furnished by Vermillion, Inc. on December 23, 2014.
6


SCHEDULE 13D
CUSIP No.� 92407M206
Page 7 of 12 pages
1
NAMES OF REPORTING PERSONS
Oracle Institutional Partners, L.P.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)� 
(b)� 
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
OO
5
CHECK IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
� 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
972,222
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
972,222
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
972,222
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
� 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.26%*
14
TYPE OF REPORTING PERSON (See Instructions)
PN
*� Calculated based on a total of 43,110,014 shares of common stock outstanding as of December 18, 2014, according to information furnished by Vermillion, Inc. on December 23, 2014.
7

Pursuant to Rule 13d-2 under the Act, this Amendment No. 3 to Schedule 13D (this Amendment) amends and supplements the Schedule 13D filed on May 23, 2013, as previously amended by Amendment No. 1, filed on June 13, 2013 and Amendment No. 2, filed on December 23, 2013 (as amended, the Schedule 13D), and is being filed on behalf of Oracle Partners, L.P., a Delaware limited partnership (Oracle Partners), Oracle Ten Fund Master, LP, a Cayman Islands exempted company (Oracle Ten Fund), Oracle Institutional Partners, L.P., a Delaware limited partnership (Oracle Institutional Partners), Oracle Associates, LLC, a Delaware limited liability company and the general partner of Oracle Partners, Oracle Ten Fund and Oracle Institutional Partners (Oracle Associates), Oracle Investment Management, Inc., a Delaware corporation and the investment manager to Oracle Ten Fund (Investment Manager) and Larry N. Feinberg, the managing member of Oracle Associates and the sole shareholder, director and president of the Investment Manager (each of the foregoing, a Reporting Person and collectively, the Reporting Persons).� This Amendment relates to the common stock, par value $0.001 per share (Common Stock), of Vermillion, Inc., a Delaware corporation (the Company).

The Reporting Persons are filing this Amendment to report the recent purchase of additional shares of Common Stock of the Company by Oracle Institutional Partners in a private placement.

All capitalized terms used herein which are not defined herein have the meanings given to such terms in the Schedule 13D.

Item 2.��Identity and Background.

Item 2 is hereby amended and restated in its entirety as follows:

(a)������������This Schedule 13D is being filed on behalf of the Reporting Persons: Oracle Partners, Oracle Ten Fund, Oracle Institutional Partners, Oracle Associates, Investment Manager and Larry N. Feinberg.

The Reporting Persons are filing jointly and the Amended Joint Filing Agreement among the Reporting Persons to file this Amendment to the Schedule 13D jointly in accordance with Rule 13d-1(k) of the Exchange Act is attached hereto as Exhibit 5.

(b)������������The address of the principal office of the Reporting Persons is c/o Oracle Investment Management, Inc., 200 Greenwich Avenue, Greenwich, Connecticut 06830. Ms. Aileen Wiate is the chief financial officer of the Investment Manager.� Ms. Wiates business address is c/o Oracle Investment Management, Inc., 200 Greenwich Avenue, Greenwich, Connecticut 06830.� There are no other members of Oracle Associates or executive officers or directors of the Investment Manager.

(c)����������The principal business of Oracle Partners, Oracle Ten Fund and Oracle Institutional Partners is to invest in securities. The principal business of Oracle Associates is to act as general partner to, and exercise investment discretion over securities held by, Oracle Partners, Oracle Institutional Partners and certain other entities.� The principal business of the Investment Manager is to exercise investment discretion over Oracle Ten Fund and certain other entities.� The principal business of Mr. Feinberg is to invest in securities through Oracle Associates, the Investment Manager and certain other entities.� Ms. Wiates principal occupation is to act as chief financial officer to the Investment Manager.
8

(d)������������None of the Reporting Persons has, nor, to their knowledge, has Ms. Wiate, during the last five years been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)������������None of the Reporting Persons has, nor, to their knowledge, has Ms. Wiate, during the last five years been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)����������Each of Oracle Partners, Oracle Institutional Partners, Oracle Associates and Investment Manager is organized under the laws of Delaware.� Oracle Ten Fund is organized under the laws of the Cayman Islands.� Mr. Feinberg is a citizen of the United States of America. Ms. Wiate is a citizen of the United States of America.

Item 3.��Source and Amount of Funds.

Item 3 is hereby amended by inserting the following at the end thereof:

The aggregate purchase price for the additional 972,222 shares of Common Stock acquired by Oracle Institutional Partners was $1,399,999.68.� In connection with this purchase of Common Stock, Oracle Institutional Partners also acquired a warrant (the OIP Warrant) to purchase 583,333 shares of Common Stock at an exercise price of $2.00 per share of Common Stock for an aggregate purchase price of $72,916.63 ($0.125 per share of Common Stock subject to the OIP Warrant).� The OIP Warrant is not exercisable until the date that is six months following the date of issuance and thus the Common Stock underlying such OIP Warrant is not currently deemed beneficially owned by the Reporting Persons.

All of the funds required to acquire the additional shares of Common Stock and the OIP Warrant were furnished from the working capital of Oracle Institutional Partners.

Item 4.��Interest in Securities of the Issuer.

The first sentence of the first paragraph of Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows:

The acquisition by Oracle Partners, Oracle Ten Fund and Oracle Institutional Partners of the Common Stock, the Warrants and the OIP Warrant was effected because of the belief of the Reporting Persons that the Common Stock represented, and continues to represent, an attractive investment.

9

The following is hereby inserted immediately preceding the paragraph with the heading Purchase Agreement in Item 4 of the Schedule 13D:

On December 19, 2014, Oracle Institutional Partners entered into a Securities Purchase Agreement (the OIP Purchase Agreement) with the Company and other purchasers named therein.� Pursuant to the terms of the OIP Purchase Agreement, on December 23, 2014, the date of the closing, (i) Oracle Institutional Partners purchased 972,222 shares of Common Stock for an aggregate purchase price of $1,399,999.68 and (ii) Oracle Institutional Partners acquired the OIP Warrant for an aggregate purchase price of $72,916.63 to purchase 583,333 shares of Common Stock.

The following summaries of the OIP Purchase Agreement and the OIP Warrant are not intended to be complete.� The OIP Purchase Agreement and the OIP Warrant, copies of which are attached hereto as Exhibit 6 and Exhibit 7 respectively, are incorporated herein by reference and the following summaries are qualified in their entirety by reference thereto.� This Amendment does not purport to amend, qualify or in any way modify such agreements.

The following is hereby inserted immediately preceding the paragraph with the heading Additional Disclosure in Item 4 of the Schedule 13D:

OIP Purchase Agreement

Pursuant to the OIP Purchase Agreement, and the transactions contemplated thereby, on December 23, 2014, the Company sold pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder, to the purchasers named in the OIP Purchase Agreement, including Oracle Institutional Partners, an aggregate of 6,944,445 shares of Common Stock at a price per share equal to $1.44 and warrants to purchase an aggregate of 4,166,662 shares of Common Stock for a price of $0.125 per share of Common Stock subject to such warrants with an exercise price of $2.00 per share.

The OIP Purchase Agreement provides for demand registration rights for Oracle Institutional Partners, among others, that will require the Company to register their shares of Common Stock, including those underlying the OIP Warrant, with the Securities Exchange Commission and permit Oracle Institutional Partners to sell such registered shares of Common Stock to the public, subject to specified conditions therein.� The Purchase Agreement also provided for the manner of allocation of the fees and expenses between the parties.

OIP Warrant

Pursuant to the OIP Warrant, issued on December 23, 2014, Oracle Institutional Partners has a right to purchase 583,333 shares of Common Stock at an exercise price per share equal to $2.00.� The warrants are exercisable commencing on the date that is six months following the date of issuance until the date that is three years after the date of issuance. The exercise price and number of shares of Common Stock subject to the OIP Warrant are subject to adjustment from time to time in accordance with the terms set forth therein.

10


Item 5.��Interest in Securities of the Issuer.

Item 5 is hereby amended and restated in its entirety as follows:

(a)������������As of December 23, 2014, Oracle Partners may be deemed to beneficially own 4,543,980 shares of Common Stock, representing 10.54% of the outstanding shares of Common Stock (based on 43,110,014 shares of Common Stock outstanding as of December 18, 2014 as reported by the Company to representatives of the Reporting Persons).� As of December 23, 2014, Oracle Institutional Partners may be deemed to beneficially own 972,222 shares of Common Stock, representing 2.26% of the outstanding shares of Common Stock (based on 43,110,014 shares of Common Stock outstanding as of December 18, 2014 as reported by the Company to representatives of the Reporting Persons). As of December 23, 2014, Oracle Ten Fund and Investment Manager, due to its relationship with Oracle Ten Fund, may be deemed to beneficially own 2,595,980 shares of Common Stock, representing 6.02% of the outstanding shares of Common Stock (based on 43,110,014 shares of Common Stock outstanding as of December 18, 2014 as reported by the Company to representatives of the Reporting Persons).� As of December 23, 2014, Oracle Associates, due to its relationship with Oracle Partners, Oracle Ten Fund and Oracle Institutional Partners, and Mr. Feinberg, due to his respective relationships with the other Reporting Persons, may be deemed to beneficially own 8,112,182 shares of Common Stock, representing 18.82% of the outstanding shares of Common Stock (based on 43,110,014 shares of Common Stock outstanding as of December 18, 2014 as reported by the Company to representatives of the Reporting Persons).� The Reporting Persons may be deemed to constitute a person or group within the meaning of Section 13(d)(3) of the Exchange Act. The filing of this Schedule 13D shall not be construed as an admission of such beneficial ownership or that the Reporting Persons constitute a person or a group.

(b)������������Each of the Reporting Persons shares the power to vote or to direct the vote and to dispose or to direct the disposition of the shares of Common Stock it may be deemed to beneficially own as described in Item 5(a) above.

(c)������������As set forth above, pursuant to the OIP Purchase Agreement, on December 23, 2014, (i) Oracle Institutional Partners purchased 972,222 shares of Common Stock for an aggregate purchase price of $1,399,999.68 and (ii) Oracle Institutional Partners acquired the OIP Warrant for an aggregate purchase price of $72,916.63 to purchase 583,333 shares of Common Stock. The OIP Warrant is not exercisable until the date that is six months following the date of issuance and thus the Common Stock underlying such OIP Warrant is not currently deemed beneficially owned by the Reporting Persons.

(d)������������Except as set forth in this Item 5 and for persons referred to in Item 2 above, no person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock that may be deemed to be beneficially owned by the Reporting Persons.

11

(e)������������Not applicable.

Item 6.��Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Item 6 is hereby amended by inserting the following at the end thereof:

On December 24, 2014, the Reporting Persons entered into an Amended Joint Filing Agreement with respect to the joint filing of this Amendment to the Schedule 13D and any subsequent amendment or amendments hereto (the Amended Joint Filing Agreement).� The Amended Joint Filing Agreement is attached hereto as Exhibit 5 and incorporated by reference.

As also described in Item 4 hereto, (i) Oracle Institutional Partners, the other purchasers named therein and the Company have entered into the OIP Purchase Agreement and (ii) Oracle Institutional Partners acquired the OIP Warrant.� The information set forth in Item 4 with respect to the OIP Purchase Agreement and the OIP Warrant is incorporated into this Item 6 by reference.

Item 7.��Material to Be Filed as Exhibits.
Item 7 is hereby amended by inserting the following at the end thereof:
Exhibit 5.
Amended Joint Filing Agreement, dated as of December 24, 2014, by and among Oracle Partners, L.P., Oracle Ten Fund Master, LP, Oracle Institutional Partners, L.P., Oracle Associates, LLC, Oracle Investment Management, Inc. and Larry N. Feinberg.
Exhibit 6.
Securities Purchase Agreement, dated as of December 19, 2014, by and among the Company, Oracle Institutional Partners, L.P. and the other purchasers named therein (incorporated by reference to Exhibit 99.1 to Vermillion, Inc.s Current Report on Form 8-K, filed on December 24, 2014).
Exhibit 7.
Warrant as to the purchase by Oracle Institutional Partners, L.P. of shares of Common Stock of the Company, dated as of December 23, 2014.

12


SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated:� December 24, 2014
ORACLE PARTNERS, L.P.
By:� ORACLE ASSOCIATES, LLC, its general partner
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated: December 24, 2014
ORACLE TEN FUND MASTER, LP
By:� ORACLE ASSOCIATES, LLC, its general partner
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated:� December 24, 2014
ORACLE INSTITUTIONAL PARTNERS, L.P.
By:� ORACLE ASSOCIATES, LLC, its general partner
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated:� December 24, 2014
ORACLE ASSOCIATES, LLC
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated:� December 24, 2014
ORACLE INVESTMENT MANAGEMENT, INC.
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated:� December 24, 2014
LARRY N. FEINBERG
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
�������������������������������������������������������������������������������������������������

Exhibit 5
AMENDED JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of the Company and further agree that this Amended Joint Filing Agreement be included as an Exhibit to such joint filings.

Dated:� December 24, 2014
ORACLE PARTNERS, L.P.
By:� ORACLE ASSOCIATES, LLC, its general partner
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated: December 24, 2014
ORACLE TEN FUND MASTER, LP
By:� ORACLE ASSOCIATES, LLC, its general partner
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated:� December 24, 2014
ORACLE INSTITUTIONAL PARTNERS, L.P.
By:� ORACLE ASSOCIATES, LLC, its general partner
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated:� December 24, 2014
ORACLE ASSOCIATES, LLC
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member

Dated:� December 24, 2014
ORACLE INVESTMENT MANAGEMENT, INC.
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
Name:� Larry N. Feinberg
Title:� � Managing Member
Dated:� December 24, 2014
LARRY N. FEINBERG
By: /s/ Larry N. Feinberg��������������������������������������������������������������������������������������������������
�������������������������������������������������������������������������������������������������


Exhibit 7
NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE SECURITIES), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS.
VERMILLION, INC.
WARRANT
Warrant No. 2014 - 6
Date of Issuance: December 23, 2014
Vermillion, Inc., a Delaware corporation (the Company), hereby certifies that, for value received, Oracle Institutional Partners, L.P., or its registered assign (the Holder), is entitled to purchase from the Company, subject to Section 6(b), 583,333 shares (as adjusted from time to time as provided in Section 12) of common stock, par value $0.001 per share, of the Company (the Common Stock) (each such share, a Warrant Share and all such shares, the Warrant Shares), at an exercise price determined pursuant to Section 3 (the Exercise Price), at any time and from time to time from and after the date that is six months following the date of issuance set forth above through and including the date that is three years following the date of issuance set forth above (the Expiration Date), and subject to the following terms and conditions:
1. Purchase Agreement. This warrant is one of a series of warrants (collectively, the Warrants) issued by the Company in connection with that certain Securities Purchase Agreement, entered into on December 19, 2014 (the Purchase Agreement), by and among the Company, the Holder and certain other Purchasers and is subject to, and the Company and the Holder shall be bound by, all of the applicable terms, conditions and provisions of the Purchase Agreement.
2. Definitions. In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein shall have the meanings assigned to such terms in the Purchase Agreement.
3. Exercise Price. This Warrant may be exercised for a price per Warrant Share equal to $2.00, subject to adjustment from time to time pursuant to Section 12 (the Exercise Price).
4. Registration of Warrant. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the Warrant Register), in the name of the record Holder hereof from time to time. The Company may deem and treat the Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.
1

5. Registration of Transfers. Subject to the Holders appropriate compliance with the restrictive legend on this Warrant, the Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment substantially in the form attached hereto as Attachment B duly completed and signed, to the Company at its address specified herein. Upon any such registration and transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (any such new Warrant, a New Warrant), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.
6. Exercise and Duration of Warrants.
(a) This Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the date that is six months after the date hereof to and including the Expiration Date. At 6:30 p.m., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. The Company may not call or redeem all or any portion of this Warrant without the prior written consent of the Holder.
(b) Notwithstanding anything contained herein to the contrary, the Company shall not effect any exercise of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, to the extent that, after giving effect to such exercise, the Holder (together with the Holders affiliates and any other persons acting as a group together with the Holder or any of the Holders affiliates), would beneficially own in excess of 19.99% of the outstanding shares of Common Stock. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock that would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other securities of the Company or its subsidiaries that would entitle the holder thereof to acquire at any time shares of Common Stock) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its affiliates.� Except as set forth in the preceding sentence, for purposes of this Section 6(b), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and the rules and regulations promulgated thereunder.
2

In addition, for purposes of this Section 6(b), group has the meaning set forth in Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.�� To the extent that the limitation contained in this Section 6(b) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of an Exercise Notice (as defined below)� shall be deemed to be the Holders representation and warranty to the Company as to whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which portion of this Warrant is exercisable, in accordance with the first sentence of this Section 6(b).� For purposes of this Section 6(b), in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (i) the Companys most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (ii) a more recent public announcement by the Company or (iii) a more recent notice by the Company or the Companys transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding.� Upon the request of the Holder, the Company shall promptly, and in any event within one trading day of such request, confirm to the Holder the number shares of Common Stock then outstanding.
7. Delivery of Warrant Shares.
(a) To effect conversions hereunder, the Holder shall not be required to physically surrender this Warrant unless the total number of Warrant Shares (as adjusted from time to time as provided in Section 12) represented by this Warrant is being exercised. Upon delivery of an Exercise Notice substantially in the form attached hereto as Attachment A (an Exercise Notice) to the Company at its address for notice determined as set forth herein, and upon payment of the applicable Exercise Price multiplied by the number of Warrant Shares that the Holder intends to purchase hereunder, the Company shall promptly (but in no event later than five trading days after the Date of Exercise (as defined below)) issue and deliver, or cause its transfer agent to issue and deliver, to the Holder a certificate for the Warrant Shares issuable upon such exercise registered in the name of the Holder or its designee. A Date of Exercise means the date on which the Holder shall have delivered to the Company: (i) an Exercise Notice, appropriately completed and duly signed, and (ii) payment of the Exercise Price (by certified or official bank check, intra-bank account transfer or wire transfer) for the number of Warrant Shares so indicated by the Holder to be purchased.
(b) If by the fifth trading day after a Date of Exercise the Company fails to deliver the required number of Warrant Shares in the manner required pursuant to Section 7(a), the Holder will have the right to rescind such exercise.
(c) The Companys obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any individual, corporation, limited liability company, limited or general partnership, joint venture, association, joint-stock company, trust, unincorporated organization, government or any agency or political subdivisions thereof (each a Person) or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holders right to pursue any other remedies available to it hereunder, at law or in equity, including a decree of specific performance and/or injunctive relief with respect to the Companys failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.
3

8. Charges, Taxes and Expenses. Issuance and delivery of certificated or uncertificated shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.
9. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a new warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a new warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a new warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver this mutilated Warrant to the Company as a condition precedent to the Companys obligation to issue the new warrant.
10. Reservation of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are then issuable and deliverable upon the exercise of this entire Warrant. The Company covenants and warrants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be validly issued, fully paid and non-assessable and free and clear of any encumbrances, preemptive rights or restrictions (other than as provided in this Warrant, the Purchase Agreement or any restrictions on transfer generally imposed under applicable securities laws).
11. Notice of Certain Corporate Action. In case the Company shall propose (a) to offer to the holders of its Common Stock rights to subscribe for or to purchase any shares of Common Stock or shares of stock of any class or any other securities, rights or options, (b) to effect any reclassification of its Common Stock (other than a reclassification involving only the subdivision, or combination, of outstanding shares of Common Stock), (c) to effect any capital reorganization, (d) to effect any Fundamental Transaction (as defined below), (e) to effect the liquidation, dissolution or winding up of the Company, (f) to offer to the holders generally of its Common Stock the right to have their shares of Common Stock repurchased or redeemed or otherwise acquired by the Company or (g) to take any other action that would require the adjustment of the Exercise Price and/or the number of Warrant Shares issuable upon exercise of this Warrant, then in each such case (but without limiting the provisions of Section 12), the Company shall give to the Holder, a notice of such proposed action, which shall specify the date on which a record is to be taken for purposes of such distribution of offer of rights, the date on which such reclassification, reorganization, Fundamental Transaction, liquidation, dissolution or winding up is to take place and the date of participation therein by the holders of Common Stock, if any such date is to be fixed and shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such action on the Common Stock. Such notice shall be so given at least ten business days prior to the record date for determining holders of the Common Stock for purposes of participating in or voting on such action, or at least ten business days prior to the date of the taking of such proposed action or the date of participation therein by the holders of Common Stock, whichever shall be the earlier.
4

Such notice shall specify, in the case of any subscription or purchase rights, the date on which the holders of Common Stock shall be entitled thereto, or, in the case of any reclassification, reorganization, Fundamental Transaction, liquidation, dissolution or winding up, the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such reclassification, reorganization, Fundamental Transaction or other action. Such notice shall also state whether the action in question or the record date is subject to the effectiveness of a registration statement under the Securities Act or to a favorable vote of security holders, if either is required, and the adjustment in Exercise Price and/or number of Warrant Shares issuable upon exercise of this Warrant as a result of such reorganization, reclassification, Fundamental Transaction or other action, to the extent then determinable. No such notice shall be given if the Company reasonably determines that the giving of such notice would require disclosure of material information that the Company has a bona fide purpose for preserving as confidential or the disclosure of which would not be in the best interests of the Company.
12. Certain Adjustments. The number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this Section 12.
(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of any Warrants), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company; then in each such case (A) the Exercise Price will be adjusted by multiplying the Exercise Price then in effect by a fraction, the numerator of which equals the number of shares of Common Stock outstanding immediately after such event (excluding treasury shares, if any), and the denominator of which equals the number of shares of Common Stock outstanding immediately prior to such event (excluding treasury shares, if any), and (B) the number of Warrant Shares issuable hereunder shall be concurrently adjusted by multiplying such number by such fraction. Such adjustments will take effect on the effective date of such dividend, distribution, subdivision, combination or issuance by reclassification, as the case may be.
(b) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or a series of related transactions, (A) effects any merger or consolidation of the Company with or into another Person (other than a wholly-owned subsidiary of the Company), (B) effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets, (C) effects any reclassification, reorganization or recapitalization of the Common Stock or any
5

compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (except for issuances by reclassification contemplated by Section 12(a)(iv)) or (D) consummates a stock or share purchase or other business combination (including a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than fifty percent (50%) of the outstanding shares of Common Stock or (ii) any, direct or indirect, tender offer or exchange offer (whether by the Company or another Person or group of Persons) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property (each transaction or series of transactions referred to in clause (i) or (ii) above, a Fundamental Transaction); then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, (1) the number of shares of common stock of the successor or acquiring corporation or, if it is the surviving corporation, of the Company and (2) any additional consideration (the Alternate Consideration) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount and components of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Companys board of directors shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration (substituting the most appropriate market-based measure for the trading market in determining the daily VWAP (as defined below) from time to time for each component of the Alternate Consideration or, if no market-based measure is reasonably available for any such component, fixing the daily VWAP of such component at the value determined by such apportionment, but subject to further adjustment as provided in this Section 12). If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant of like tenor to this Warrant but adjusted to be consistent with the foregoing provisions and evidencing the Holders right to exercise such warrant for the appropriate number of shares of capital stock and Alternate Consideration, if any, in exchange for this Warrant. The Company shall ensure that the terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 12(b) and ensuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction or series of related transactions analogous to a Fundamental Transaction. VWAP means, for any date, the price determined by the first of the following clauses that applies: (A) if the Common Stock is then listed or quoted on a trading market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the principal trading market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a trading day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York City time)), (B) if prices for the Common Stock are then reported in the Pink Sheets published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported during trading hours or (C) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Companys board of directors and reasonably acceptable to the Holder, the fees and expenses of which shall be paid by the Company.
6

(c) Notice of Adjustment. Upon any adjustment of the Exercise Price, and from time to time upon the request of the Holder, the Company shall furnish to the Holder the Exercise Price resulting from such adjustment or otherwise in effect and the number of Warrant Shares then available for purchase under this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.
13. No Fractional Shares. No fractional shares of Common Stock will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the Company shall pay the Holder an amount of cash equal to the product of such fraction multiplied by the closing price of one share of Common Stock as reported on the principal trading market for the Common Stock on the Date of Exercise.
14. No Impairment. The Company shall not by any action including, without limitation, amending its certificate of incorporation, any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but shall at all times in good faith assist in the carrying out of all such terms and in the taking of all such action, as may be necessary or appropriate to protect the rights of the Holder against impairment. Without limiting the generality of the foregoing, the Company shall take all such action as may be necessary or appropriate in order that the Company may validly issue fully paid and non-assessable shares of Common Stock upon the exercise of this Warrant at the then Exercise Price therefor.
15. No Rights as a Stockholder; Notice to Holder. Nothing contained in this Warrant shall be construed as conferring upon the Holder the right to vote or to consent or to receive notice as a stockholder in respect of any meeting of stockholders for the election of directors of the Company or any other matter, or any rights whatsoever as a stockholder of the Company.
16. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon 30 days notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holders last address as shown on the Warrant Register.
17. Miscellaneous.
(a) Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or
7

communication is delivered via facsimile at the facsimile number pursuant to this Section 17(a) prior to 6:30 p.m. (New York City time) on a trading day, (ii) the next trading day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified pursuant to this Section 17(a) on a day that is not a trading day or later than 6:30 p.m. (New York City time) on any trading day, (iii) the trading day following the date of mailing, if sent by nationally recognized overnight courier service to the street address specified pursuant to this Section 17(a), or (iv) upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be as follows:
�(A) if to the Company, to:
Vermillion, Inc.
12117 Bee Caves Road
Building Three, Suite 100
Austin, Texas� 78738
Attention:� Eric Schoen
Facsimile: (512) 439-6980
with a copy to (which shall not constitute notice to the Company):
Sidley Austin LLP
One South Dearborn Street
Chicago, Illinois 60603
Attention:� Beth Flaming
Facsimile: (312) 853-7036
(B) if to the Holder, to the address, facsimile number or street address appearing on the Warrant Register (which shall initially be the facsimile number and street address set forth for the initial Holder in the Purchase Agreement);
or to such other address or facsimile number as the Company or the Holder may provide to the other in accordance with this Section 17(a).
(b) Assignment. Subject to the restrictions on transfer described herein, the rights and obligations of the Company and the Holder shall be binding upon, and inure to the benefit of, the successors, assigns, heirs, administrators and transferees of the parties. The Company shall not have the right, directly or indirectly, to assign or transfer this Warrant without the prior written consent of the Holder, which may be withheld in the Holders sole discretion, or as part of a Fundamental Transaction.
(c) No Third-Party Beneficiaries. Nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant.
(d) Amendments; Waiver. This Warrant may be amended only in writing signed by the Company and the Holder. Any provision of this Warrant may be waived, but only if in writing by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Warrant shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.
8

(e) Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to principles of conflict of laws.
(f) Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law in any respect, such provision shall be excluded from this Warrant and the balance of this Warrant shall be construed and interpreted as if such provision were so excluded and shall be enforceable in accordance with its remaining terms.
* * * * *
9


IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

VERMILLION, INC.
By:
/s/ Eric Schoen����������������������������������������
Name:
Eric Schoen
Title:
Vice President, Finance & Chief
Accounting Officer
10

ATTACHMENT A
EXERCISE NOTICE
To Vermillion, Inc.:
The undersigned hereby irrevocably elects to purchase shares (the Shares) of common stock, par value $0.001 per share (Common Stock), of Vermillion, Inc., a Delaware corporation, pursuant to Warrant No. _____, originally issued on __________ (the Warrant). The undersigned elects to utilize the following manner of exercise:
Shares:
_____��������������������Full Exercise of Warrant
_____��������������������Partial Exercise of Warrant (in the amount of __________ Shares)
Exercise Price: $_____
Manner of Exercise:
_____��������������������Certified or Official Bank Check
_____��������������������Intra-Bank Account Transfer
_____��������������������Wire Transfer
[Please issue a new warrant for the unexercised portion of the attached Warrant in the name of the [undersigned]/[the undersigneds nominee as is specified below].]
Date:
Full Name of Holder*:
Signature of Holder / Authorized Representative:
Name and Title of Authorized Representative :
Additional Signature of Holder (if jointly held):
Social Security or Tax Identification Number:
Address of Holder:
Full Name of Nominee of Holder :
Address of Nominee of Holder :
*� Must conform in all respects to name of holder as specified on the face of the Warrant.
� If applicable.
A - 1

ATTACHMENT B
FORM OF ASSIGNMENT
[To be completed and signed only upon transfer of Warrant]
FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto _______________ the right represented by the attached Warrant to purchase _______________ shares of Common Stock of Vermillion, Inc., a Delaware corporation (the Company), to which the Warrant relates and appoints _______________ as attorney to transfer said right on the books of the Company with full power of substitution in the premises.

Date:
Full Name of Holder*:
Signature of Holder / Authorized Representative:
Name and Title of Authorized Representative :
Additional Signature of Holder (if jointly held):
Address of Holder:
Full Name of Transferee:
Address of Transferee:
In the Presence of:
*� Must conform in all respects to name of holder as specified on the face of the Warrant.
� If applicable.

1


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

13D